What is the role of alemtuzumab in the treatment of granulomatosis with polyangiitis (GPA)?

Updated: Aug 31, 2021
  • Author: Christopher L Tracy, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

Anti-CD52 therapy (alemtuzumab) is a humanized monoclonal antibody to CD52 that selectively depletes lymphocyte and macrophage populations. Its use in GPA is considered experimental. [107]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!